Daix (France), Long Island City (New York, United States), March 7, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of small molecules administered oral for the treatment of nonalcoholic steatohepatitis (NASH) and other diseases with an unmet medical need, today announces the lifting of the previously announced voluntary pause of screening and randomization for its NATiV3 clinical study, and the resumption of screening activities on its sites.